Continuing its efforts in the multiple sclerosis (MS) treatment space, Biogen has agreed to in-license InnoCare’s orelabrutinib for multiple sclerosis (MS) and certain autoimmune diseases. The deal, which is worth up toUS$937.5 M, comes after Biogen witnessed a decline in MS product revenues in FY 2020 due to the generic erosion of Tecfidera® (dimethyl fumarate) and the entry of second-generation sphingosine-1-phosphate receptor modulators for treating MS. Now with the exclusive rights to orelabrutinib, Biogen will gain an opportunity to maintain its position in the global MS market.